IBDEI0D7 ; ; 03-MAY-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 03, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,33123,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33123,1,3,0)
;;=3^Solitary plasmacytoma in remission
;;^UTILITY(U,$J,358.3,33123,1,4,0)
;;=4^C90.31
;;^UTILITY(U,$J,358.3,33123,2)
;;=^5001760
;;^UTILITY(U,$J,358.3,33124,0)
;;=C88.8^^102^1380^32
;;^UTILITY(U,$J,358.3,33124,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33124,1,3,0)
;;=3^Malignant immunoproliferative diseases NEC
;;^UTILITY(U,$J,358.3,33124,1,4,0)
;;=4^C88.8
;;^UTILITY(U,$J,358.3,33124,2)
;;=^5001750
;;^UTILITY(U,$J,358.3,33125,0)
;;=C90.22^^102^1380^23
;;^UTILITY(U,$J,358.3,33125,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33125,1,3,0)
;;=3^Extramedullary plasmacytoma in relapse
;;^UTILITY(U,$J,358.3,33125,1,4,0)
;;=4^C90.22
;;^UTILITY(U,$J,358.3,33125,2)
;;=^5001758
;;^UTILITY(U,$J,358.3,33126,0)
;;=C90.32^^102^1380^54
;;^UTILITY(U,$J,358.3,33126,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33126,1,3,0)
;;=3^Solitary plasmacytoma in relapse
;;^UTILITY(U,$J,358.3,33126,1,4,0)
;;=4^C90.32
;;^UTILITY(U,$J,358.3,33126,2)
;;=^5001761
;;^UTILITY(U,$J,358.3,33127,0)
;;=C91.01^^102^1380^2
;;^UTILITY(U,$J,358.3,33127,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33127,1,3,0)
;;=3^Acute lymphoblastic leukemia, in remission
;;^UTILITY(U,$J,358.3,33127,1,4,0)
;;=4^C91.01
;;^UTILITY(U,$J,358.3,33127,2)
;;=^5001763
;;^UTILITY(U,$J,358.3,33128,0)
;;=C91.02^^102^1380^1
;;^UTILITY(U,$J,358.3,33128,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33128,1,3,0)
;;=3^Acute lymphoblastic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33128,1,4,0)
;;=4^C91.02
;;^UTILITY(U,$J,358.3,33128,2)
;;=^5001764
;;^UTILITY(U,$J,358.3,33129,0)
;;=C91.11^^102^1380^16
;;^UTILITY(U,$J,358.3,33129,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33129,1,3,0)
;;=3^Chronic lymphocytic leukemia of B-cell type in remission
;;^UTILITY(U,$J,358.3,33129,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,33129,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,33130,0)
;;=C91.12^^102^1380^17
;;^UTILITY(U,$J,358.3,33130,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33130,1,3,0)
;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
;;^UTILITY(U,$J,358.3,33130,1,4,0)
;;=4^C91.12
;;^UTILITY(U,$J,358.3,33130,2)
;;=^5001767
;;^UTILITY(U,$J,358.3,33131,0)
;;=C91.Z1^^102^1380^31
;;^UTILITY(U,$J,358.3,33131,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33131,1,3,0)
;;=3^Lymphoid leukemia, in remission NEC
;;^UTILITY(U,$J,358.3,33131,1,4,0)
;;=4^C91.Z1
;;^UTILITY(U,$J,358.3,33131,2)
;;=^5001787
;;^UTILITY(U,$J,358.3,33132,0)
;;=C91.Z2^^102^1380^30
;;^UTILITY(U,$J,358.3,33132,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33132,1,3,0)
;;=3^Lymphoid leukemia, in relapse NEC
;;^UTILITY(U,$J,358.3,33132,1,4,0)
;;=4^C91.Z2
;;^UTILITY(U,$J,358.3,33132,2)
;;=^5001788
;;^UTILITY(U,$J,358.3,33133,0)
;;=C92.01^^102^1380^6
;;^UTILITY(U,$J,358.3,33133,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33133,1,3,0)
;;=3^Acute myeloblastic leukemia, in remission
;;^UTILITY(U,$J,358.3,33133,1,4,0)
;;=4^C92.01
;;^UTILITY(U,$J,358.3,33133,2)
;;=^5001790
;;^UTILITY(U,$J,358.3,33134,0)
;;=C92.41^^102^1380^10
;;^UTILITY(U,$J,358.3,33134,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33134,1,3,0)
;;=3^Acute promyelocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,33134,1,4,0)
;;=4^C92.41
;;^UTILITY(U,$J,358.3,33134,2)
;;=^5001802
;;^UTILITY(U,$J,358.3,33135,0)
;;=C92.51^^102^1380^8
;;^UTILITY(U,$J,358.3,33135,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33135,1,3,0)
;;=3^Acute myelomonocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,33135,1,4,0)
;;=4^C92.51
;;^UTILITY(U,$J,358.3,33135,2)
;;=^5001805
;;^UTILITY(U,$J,358.3,33136,0)
;;=C92.02^^102^1380^5
;;^UTILITY(U,$J,358.3,33136,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33136,1,3,0)
;;=3^Acute myeloblastic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33136,1,4,0)
;;=4^C92.02
;;^UTILITY(U,$J,358.3,33136,2)
;;=^5001791
;;^UTILITY(U,$J,358.3,33137,0)
;;=C92.42^^102^1380^9
;;^UTILITY(U,$J,358.3,33137,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33137,1,3,0)
;;=3^Acute promyelocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33137,1,4,0)
;;=4^C92.42
;;^UTILITY(U,$J,358.3,33137,2)
;;=^5001803
;;^UTILITY(U,$J,358.3,33138,0)
;;=C92.52^^102^1380^7
;;^UTILITY(U,$J,358.3,33138,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33138,1,3,0)
;;=3^Acute myelomonocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33138,1,4,0)
;;=4^C92.52
;;^UTILITY(U,$J,358.3,33138,2)
;;=^5001806
;;^UTILITY(U,$J,358.3,33139,0)
;;=C92.11^^102^1380^18
;;^UTILITY(U,$J,358.3,33139,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33139,1,3,0)
;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
;;^UTILITY(U,$J,358.3,33139,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,33139,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,33140,0)
;;=C92.12^^102^1380^19
;;^UTILITY(U,$J,358.3,33140,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33140,1,3,0)
;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
;;^UTILITY(U,$J,358.3,33140,1,4,0)
;;=4^C92.12
;;^UTILITY(U,$J,358.3,33140,2)
;;=^5001794
;;^UTILITY(U,$J,358.3,33141,0)
;;=C92.21^^102^1380^13
;;^UTILITY(U,$J,358.3,33141,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33141,1,3,0)
;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
;;^UTILITY(U,$J,358.3,33141,1,4,0)
;;=4^C92.21
;;^UTILITY(U,$J,358.3,33141,2)
;;=^5001796
;;^UTILITY(U,$J,358.3,33142,0)
;;=C92.22^^102^1380^14
;;^UTILITY(U,$J,358.3,33142,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33142,1,3,0)
;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
;;^UTILITY(U,$J,358.3,33142,1,4,0)
;;=4^C92.22
;;^UTILITY(U,$J,358.3,33142,2)
;;=^5001797
;;^UTILITY(U,$J,358.3,33143,0)
;;=C93.01^^102^1380^3
;;^UTILITY(U,$J,358.3,33143,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33143,1,3,0)
;;=3^Acute monoblastic/monocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,33143,1,4,0)
;;=4^C93.01
;;^UTILITY(U,$J,358.3,33143,2)
;;=^5001820
;;^UTILITY(U,$J,358.3,33144,0)
;;=C93.02^^102^1380^4
;;^UTILITY(U,$J,358.3,33144,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33144,1,3,0)
;;=3^Acute monoblastic/monocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33144,1,4,0)
;;=4^C93.02
;;^UTILITY(U,$J,358.3,33144,2)
;;=^5001821
;;^UTILITY(U,$J,358.3,33145,0)
;;=C93.11^^102^1380^21
;;^UTILITY(U,$J,358.3,33145,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33145,1,3,0)
;;=3^Chronic myelomonocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,33145,1,4,0)
;;=4^C93.11
;;^UTILITY(U,$J,358.3,33145,2)
;;=^5001823
;;^UTILITY(U,$J,358.3,33146,0)
;;=C93.12^^102^1380^20
;;^UTILITY(U,$J,358.3,33146,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33146,1,3,0)
;;=3^Chronic myelomonocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,33146,1,4,0)
;;=4^C93.12
;;^UTILITY(U,$J,358.3,33146,2)
;;=^5001824
;;^UTILITY(U,$J,358.3,33147,0)
;;=C93.91^^102^1380^40
;;^UTILITY(U,$J,358.3,33147,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33147,1,3,0)
;;=3^Monocytic leukemia, unspecified in remission
;;^UTILITY(U,$J,358.3,33147,1,4,0)
;;=4^C93.91
;;^UTILITY(U,$J,358.3,33147,2)
;;=^5001829
;;^UTILITY(U,$J,358.3,33148,0)
;;=C93.92^^102^1380^39
;;^UTILITY(U,$J,358.3,33148,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33148,1,3,0)
;;=3^Monocytic leukemia, unspecified in relapse
;;^UTILITY(U,$J,358.3,33148,1,4,0)
;;=4^C93.92
;;^UTILITY(U,$J,358.3,33148,2)
;;=^5001830
;;^UTILITY(U,$J,358.3,33149,0)
;;=E88.3^^102^1380^56
;;^UTILITY(U,$J,358.3,33149,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33149,1,3,0)
;;=3^Tumor lysis syndrome
;;^UTILITY(U,$J,358.3,33149,1,4,0)
;;=4^E88.3
;;^UTILITY(U,$J,358.3,33149,2)
;;=^338229
;;^UTILITY(U,$J,358.3,33150,0)
;;=C96.20^^102^1380^33
;;^UTILITY(U,$J,358.3,33150,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33150,1,3,0)
;;=3^Malignant mast cell neoplasm, unspecified
;;^UTILITY(U,$J,358.3,33150,1,4,0)
;;=4^C96.20
;;^UTILITY(U,$J,358.3,33150,2)
;;=^5151293
;;^UTILITY(U,$J,358.3,33151,0)
;;=C96.21^^102^1380^35
;;^UTILITY(U,$J,358.3,33151,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33151,1,3,0)
;;=3^Mastocytosis, aggressive systemic
;;^UTILITY(U,$J,358.3,33151,1,4,0)
;;=4^C96.21
;;^UTILITY(U,$J,358.3,33151,2)
;;=^5151294
;;^UTILITY(U,$J,358.3,33152,0)
;;=C96.22^^102^1380^52
;;^UTILITY(U,$J,358.3,33152,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33152,1,3,0)
;;=3^Sarcoma, mast cell
;;^UTILITY(U,$J,358.3,33152,1,4,0)
;;=4^C96.22
;;^UTILITY(U,$J,358.3,33152,2)
;;=^5151295
;;^UTILITY(U,$J,358.3,33153,0)
;;=C96.29^^102^1380^45
;;^UTILITY(U,$J,358.3,33153,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33153,1,3,0)
;;=3^Neoplasm, mast cell, oth malignant
;;^UTILITY(U,$J,358.3,33153,1,4,0)
;;=4^C96.29
;;^UTILITY(U,$J,358.3,33153,2)
;;=^5151296
;;^UTILITY(U,$J,358.3,33154,0)
;;=D47.01^^102^1380^36
;;^UTILITY(U,$J,358.3,33154,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33154,1,3,0)
;;=3^Mastocytosis, cutaneous
;;^UTILITY(U,$J,358.3,33154,1,4,0)
;;=4^D47.01
;;^UTILITY(U,$J,358.3,33154,2)
;;=^5151297
;;^UTILITY(U,$J,358.3,33155,0)
;;=D47.02^^102^1380^37
;;^UTILITY(U,$J,358.3,33155,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33155,1,3,0)
;;=3^Mastocytosis, systemic
;;^UTILITY(U,$J,358.3,33155,1,4,0)
;;=4^D47.02
;;^UTILITY(U,$J,358.3,33155,2)
;;=^5151298
;;^UTILITY(U,$J,358.3,33156,0)
;;=D47.09^^102^1380^46
;;^UTILITY(U,$J,358.3,33156,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33156,1,3,0)
;;=3^Neoplasms, mast cell, oth, of uncertain behavior
;;^UTILITY(U,$J,358.3,33156,1,4,0)
;;=4^D47.09
;;^UTILITY(U,$J,358.3,33156,2)
;;=^5151299
;;^UTILITY(U,$J,358.3,33157,0)
;;=C62.11^^102^1381^2
;;^UTILITY(U,$J,358.3,33157,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33157,1,3,0)
;;=3^Malignant neoplasm of descended right testis
;;^UTILITY(U,$J,358.3,33157,1,4,0)
;;=4^C62.11
;;^UTILITY(U,$J,358.3,33157,2)
;;=^5001234
;;^UTILITY(U,$J,358.3,33158,0)
;;=C62.12^^102^1381^1
;;^UTILITY(U,$J,358.3,33158,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33158,1,3,0)
;;=3^Malignant neoplasm of descended left testis
;;^UTILITY(U,$J,358.3,33158,1,4,0)
;;=4^C62.12
;;^UTILITY(U,$J,358.3,33158,2)
;;=^5001235
;;^UTILITY(U,$J,358.3,33159,0)
;;=M81.0^^102^1382^1
;;^UTILITY(U,$J,358.3,33159,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33159,1,3,0)
;;=3^Age-related osteoporosis w/o current pathological fracture
;;^UTILITY(U,$J,358.3,33159,1,4,0)
;;=4^M81.0
;;^UTILITY(U,$J,358.3,33159,2)
;;=^5013555
;;^UTILITY(U,$J,358.3,33160,0)
;;=E10.9^^102^1382^5
;;^UTILITY(U,$J,358.3,33160,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33160,1,3,0)
;;=3^Diabetes Type 1 w/o Complications
;;^UTILITY(U,$J,358.3,33160,1,4,0)
;;=4^E10.9
;;^UTILITY(U,$J,358.3,33160,2)
;;=^5002626
;;^UTILITY(U,$J,358.3,33161,0)
;;=E11.9^^102^1382^8
;;^UTILITY(U,$J,358.3,33161,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33161,1,3,0)
;;=3^Diabetes Type 2 w/o Complications
;;^UTILITY(U,$J,358.3,33161,1,4,0)
;;=4^E11.9
;;^UTILITY(U,$J,358.3,33161,2)
;;=^5002666
;;^UTILITY(U,$J,358.3,33162,0)
;;=E11.10^^102^1382^7
;;^UTILITY(U,$J,358.3,33162,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33162,1,3,0)
;;=3^Diabetes Type 2 w/ Ketoacidosis w/o Coma
;;^UTILITY(U,$J,358.3,33162,1,4,0)
;;=4^E11.10
;;^UTILITY(U,$J,358.3,33162,2)
;;=^5151300
;;^UTILITY(U,$J,358.3,33163,0)
;;=E11.11^^102^1382^6
;;^UTILITY(U,$J,358.3,33163,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33163,1,3,0)
;;=3^Diabetes Type 2 w/ Ketoacidosis w/ Coma
;;^UTILITY(U,$J,358.3,33163,1,4,0)
;;=4^E11.11
;;^UTILITY(U,$J,358.3,33163,2)
;;=^5151301
;;^UTILITY(U,$J,358.3,33164,0)
;;=E85.81^^102^1382^2
;;^UTILITY(U,$J,358.3,33164,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33164,1,3,0)
;;=3^Amyloidosis,Light Chain (AL)
;;^UTILITY(U,$J,358.3,33164,1,4,0)
;;=4^E85.81
;;^UTILITY(U,$J,358.3,33164,2)
;;=^5151302
;;^UTILITY(U,$J,358.3,33165,0)
;;=E85.82^^102^1382^4
;;^UTILITY(U,$J,358.3,33165,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33165,1,3,0)
;;=3^Amyloidosis,Wild-Type Transthyretin-Related (ATTR)
;;^UTILITY(U,$J,358.3,33165,1,4,0)
;;=4^E85.82
;;^UTILITY(U,$J,358.3,33165,2)
;;=^5151303
;;^UTILITY(U,$J,358.3,33166,0)
;;=E85.89^^102^1382^3
;;^UTILITY(U,$J,358.3,33166,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33166,1,3,0)
;;=3^Amyloidosis,Other
;;^UTILITY(U,$J,358.3,33166,1,4,0)
;;=4^E85.89
;;^UTILITY(U,$J,358.3,33166,2)
;;=^334034
;;^UTILITY(U,$J,358.3,33167,0)
;;=R10.9^^102^1383^2
;;^UTILITY(U,$J,358.3,33167,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33167,1,3,0)
;;=3^Abdominal Pain,Unspec
;;^UTILITY(U,$J,358.3,33167,1,4,0)
;;=4^R10.9
;;^UTILITY(U,$J,358.3,33167,2)
;;=^5019230
;;^UTILITY(U,$J,358.3,33168,0)
;;=R10.11^^102^1383^47
;;^UTILITY(U,$J,358.3,33168,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33168,1,3,0)
;;=3^Right upper quadrant pain
;;^UTILITY(U,$J,358.3,33168,1,4,0)
;;=4^R10.11
;;^UTILITY(U,$J,358.3,33168,2)
;;=^5019206
;;^UTILITY(U,$J,358.3,33169,0)
;;=R10.31^^102^1383^46
;;^UTILITY(U,$J,358.3,33169,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33169,1,3,0)
;;=3^Right lower quadrant pain
;;^UTILITY(U,$J,358.3,33169,1,4,0)
;;=4^R10.31
;;^UTILITY(U,$J,358.3,33169,2)
;;=^5019211
;;^UTILITY(U,$J,358.3,33170,0)
;;=R10.84^^102^1383^1
;;^UTILITY(U,$J,358.3,33170,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33170,1,3,0)
;;=3^Abdominal Pain,Generalized
;;^UTILITY(U,$J,358.3,33170,1,4,0)
;;=4^R10.84
;;^UTILITY(U,$J,358.3,33170,2)
;;=^5019229
;;^UTILITY(U,$J,358.3,33171,0)
;;=R10.10^^102^1383^49
;;^UTILITY(U,$J,358.3,33171,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33171,1,3,0)
;;=3^Upper abdominal pain, unspecified
;;^UTILITY(U,$J,358.3,33171,1,4,0)
;;=4^R10.10
;;^UTILITY(U,$J,358.3,33171,2)
;;=^5019205
;;^UTILITY(U,$J,358.3,33172,0)
;;=R10.30^^102^1383^32
;;^UTILITY(U,$J,358.3,33172,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33172,1,3,0)
;;=3^Lower abdominal pain, unspecified
;;^UTILITY(U,$J,358.3,33172,1,4,0)
;;=4^R10.30
;;^UTILITY(U,$J,358.3,33172,2)
;;=^5019210
;;^UTILITY(U,$J,358.3,33173,0)
;;=R10.2^^102^1383^40
;;^UTILITY(U,$J,358.3,33173,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33173,1,3,0)
;;=3^Pelvic and perineal pain
;;^UTILITY(U,$J,358.3,33173,1,4,0)
;;=4^R10.2
;;^UTILITY(U,$J,358.3,33173,2)
;;=^5019209
;;^UTILITY(U,$J,358.3,33174,0)
;;=R18.8^^102^1383^9
;;^UTILITY(U,$J,358.3,33174,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33174,1,3,0)
;;=3^Ascites NEC
;;^UTILITY(U,$J,358.3,33174,1,4,0)
;;=4^R18.8
;;^UTILITY(U,$J,358.3,33174,2)
;;=^5019253
;;^UTILITY(U,$J,358.3,33175,0)
;;=R19.7^^102^1383^17
;;^UTILITY(U,$J,358.3,33175,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33175,1,3,0)
;;=3^Diarrhea, unspecified
;;^UTILITY(U,$J,358.3,33175,1,4,0)
;;=4^R19.7
;;^UTILITY(U,$J,358.3,33175,2)
;;=^5019276
;;^UTILITY(U,$J,358.3,33176,0)
;;=R11.2^^102^1383^36
;;^UTILITY(U,$J,358.3,33176,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33176,1,3,0)
;;=3^Nausea with vomiting, unspecified
;;^UTILITY(U,$J,358.3,33176,1,4,0)
;;=4^R11.2
;;^UTILITY(U,$J,358.3,33176,2)
;;=^5019237
;;^UTILITY(U,$J,358.3,33177,0)
;;=R11.0^^102^1383^35
;;^UTILITY(U,$J,358.3,33177,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33177,1,3,0)
;;=3^Nausea
;;^UTILITY(U,$J,358.3,33177,1,4,0)
;;=4^R11.0
;;^UTILITY(U,$J,358.3,33177,2)
;;=^5019231
;;^UTILITY(U,$J,358.3,33178,0)
;;=R11.10^^102^1383^51
;;^UTILITY(U,$J,358.3,33178,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33178,1,3,0)
;;=3^Vomiting, unspecified
;;^UTILITY(U,$J,358.3,33178,1,4,0)
;;=4^R11.10
;;^UTILITY(U,$J,358.3,33178,2)
;;=^5019232
;;^UTILITY(U,$J,358.3,33179,0)
;;=R11.11^^102^1383^50
;;^UTILITY(U,$J,358.3,33179,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33179,1,3,0)
;;=3^Vomiting without nausea
;;^UTILITY(U,$J,358.3,33179,1,4,0)
;;=4^R11.11
;;^UTILITY(U,$J,358.3,33179,2)
;;=^5019233
;;^UTILITY(U,$J,358.3,33180,0)
;;=R11.12^^102^1383^42
;;^UTILITY(U,$J,358.3,33180,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33180,1,3,0)
;;=3^Projectile vomiting
;;^UTILITY(U,$J,358.3,33180,1,4,0)
;;=4^R11.12
;;^UTILITY(U,$J,358.3,33180,2)
;;=^5019234
;;^UTILITY(U,$J,358.3,33181,0)
;;=R62.7^^102^1383^5
;;^UTILITY(U,$J,358.3,33181,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33181,1,3,0)
;;=3^Adult failure to thrive
;;^UTILITY(U,$J,358.3,33181,1,4,0)
;;=4^R62.7
;;^UTILITY(U,$J,358.3,33181,2)
;;=^322019
;;^UTILITY(U,$J,358.3,33182,0)
;;=R60.9^^102^1383^19
;;^UTILITY(U,$J,358.3,33182,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33182,1,3,0)
;;=3^Edema, unspecified
;;^UTILITY(U,$J,358.3,33182,1,4,0)
;;=4^R60.9
;;^UTILITY(U,$J,358.3,33182,2)
;;=^5019534
;;^UTILITY(U,$J,358.3,33183,0)
;;=R60.1^^102^1383^20
;;^UTILITY(U,$J,358.3,33183,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33183,1,3,0)
;;=3^Edema,Generalized
;;^UTILITY(U,$J,358.3,33183,1,4,0)
;;=4^R60.1
;;^UTILITY(U,$J,358.3,33183,2)
;;=^5019533
;;^UTILITY(U,$J,358.3,33184,0)
;;=R60.0^^102^1383^21
;;^UTILITY(U,$J,358.3,33184,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33184,1,3,0)
;;=3^Edema,Localized
;;^UTILITY(U,$J,358.3,33184,1,4,0)
;;=4^R60.0
;;^UTILITY(U,$J,358.3,33184,2)
;;=^5019532
;;^UTILITY(U,$J,358.3,33185,0)
;;=L29.9^^102^1383^45
;;^UTILITY(U,$J,358.3,33185,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33185,1,3,0)
;;=3^Pruritus, unspecified
;;^UTILITY(U,$J,358.3,33185,1,4,0)
;;=4^L29.9
;;^UTILITY(U,$J,358.3,33185,2)
;;=^5009153
;;^UTILITY(U,$J,358.3,33186,0)
;;=I95.9^^102^1383^28
;;^UTILITY(U,$J,358.3,33186,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33186,1,3,0)
;;=3^Hypotension, unspecified
;;^UTILITY(U,$J,358.3,33186,1,4,0)
;;=4^I95.9
;;^UTILITY(U,$J,358.3,33186,2)
;;=^5008080
;;^UTILITY(U,$J,358.3,33187,0)
;;=I10.^^102^1383^24
;;^UTILITY(U,$J,358.3,33187,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33187,1,3,0)
;;=3^Essential (primary) hypertension
;;^UTILITY(U,$J,358.3,33187,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,33187,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,33188,0)
;;=G89.29^^102^1383^13
;;^UTILITY(U,$J,358.3,33188,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33188,1,3,0)
;;=3^Chronic Pain NEC
;;^UTILITY(U,$J,358.3,33188,1,4,0)
;;=4^G89.29
;;^UTILITY(U,$J,358.3,33188,2)
;;=^5004158
;;^UTILITY(U,$J,358.3,33189,0)
;;=F41.9^^102^1383^8
;;^UTILITY(U,$J,358.3,33189,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33189,1,3,0)
;;=3^Anxiety disorder, unspecified
;;^UTILITY(U,$J,358.3,33189,1,4,0)
;;=4^F41.9
;;^UTILITY(U,$J,358.3,33189,2)
;;=^5003567
;;^UTILITY(U,$J,358.3,33190,0)
;;=F33.9^^102^1383^34
;;^UTILITY(U,$J,358.3,33190,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,33190,1,3,0)
;;=3^Major depressive disorder, recurrent, unspecified
;;^UTILITY(U,$J,358.3,33190,1,4,0)
;;=4^F33.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0D7 19763 printed Apr 09, 2024@21:28:51 Page 2
IBDEI0D7 ; ; 03-MAY-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 03, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,33123,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,33123,1,3,0)
+4 ;;=3^Solitary plasmacytoma in remission
+5 ;;^UTILITY(U,$J,358.3,33123,1,4,0)
+6 ;;=4^C90.31
+7 ;;^UTILITY(U,$J,358.3,33123,2)
+8 ;;=^5001760
+9 ;;^UTILITY(U,$J,358.3,33124,0)
+10 ;;=C88.8^^102^1380^32
+11 ;;^UTILITY(U,$J,358.3,33124,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,33124,1,3,0)
+14 ;;=3^Malignant immunoproliferative diseases NEC
+15 ;;^UTILITY(U,$J,358.3,33124,1,4,0)
+16 ;;=4^C88.8
+17 ;;^UTILITY(U,$J,358.3,33124,2)
+18 ;;=^5001750
+19 ;;^UTILITY(U,$J,358.3,33125,0)
+20 ;;=C90.22^^102^1380^23
+21 ;;^UTILITY(U,$J,358.3,33125,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,33125,1,3,0)
+24 ;;=3^Extramedullary plasmacytoma in relapse
+25 ;;^UTILITY(U,$J,358.3,33125,1,4,0)
+26 ;;=4^C90.22
+27 ;;^UTILITY(U,$J,358.3,33125,2)
+28 ;;=^5001758
+29 ;;^UTILITY(U,$J,358.3,33126,0)
+30 ;;=C90.32^^102^1380^54
+31 ;;^UTILITY(U,$J,358.3,33126,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,33126,1,3,0)
+34 ;;=3^Solitary plasmacytoma in relapse
+35 ;;^UTILITY(U,$J,358.3,33126,1,4,0)
+36 ;;=4^C90.32
+37 ;;^UTILITY(U,$J,358.3,33126,2)
+38 ;;=^5001761
+39 ;;^UTILITY(U,$J,358.3,33127,0)
+40 ;;=C91.01^^102^1380^2
+41 ;;^UTILITY(U,$J,358.3,33127,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,33127,1,3,0)
+44 ;;=3^Acute lymphoblastic leukemia, in remission
+45 ;;^UTILITY(U,$J,358.3,33127,1,4,0)
+46 ;;=4^C91.01
+47 ;;^UTILITY(U,$J,358.3,33127,2)
+48 ;;=^5001763
+49 ;;^UTILITY(U,$J,358.3,33128,0)
+50 ;;=C91.02^^102^1380^1
+51 ;;^UTILITY(U,$J,358.3,33128,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,33128,1,3,0)
+54 ;;=3^Acute lymphoblastic leukemia, in relapse
+55 ;;^UTILITY(U,$J,358.3,33128,1,4,0)
+56 ;;=4^C91.02
+57 ;;^UTILITY(U,$J,358.3,33128,2)
+58 ;;=^5001764
+59 ;;^UTILITY(U,$J,358.3,33129,0)
+60 ;;=C91.11^^102^1380^16
+61 ;;^UTILITY(U,$J,358.3,33129,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,33129,1,3,0)
+64 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
+65 ;;^UTILITY(U,$J,358.3,33129,1,4,0)
+66 ;;=4^C91.11
+67 ;;^UTILITY(U,$J,358.3,33129,2)
+68 ;;=^5001766
+69 ;;^UTILITY(U,$J,358.3,33130,0)
+70 ;;=C91.12^^102^1380^17
+71 ;;^UTILITY(U,$J,358.3,33130,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,33130,1,3,0)
+74 ;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
+75 ;;^UTILITY(U,$J,358.3,33130,1,4,0)
+76 ;;=4^C91.12
+77 ;;^UTILITY(U,$J,358.3,33130,2)
+78 ;;=^5001767
+79 ;;^UTILITY(U,$J,358.3,33131,0)
+80 ;;=C91.Z1^^102^1380^31
+81 ;;^UTILITY(U,$J,358.3,33131,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,33131,1,3,0)
+84 ;;=3^Lymphoid leukemia, in remission NEC
+85 ;;^UTILITY(U,$J,358.3,33131,1,4,0)
+86 ;;=4^C91.Z1
+87 ;;^UTILITY(U,$J,358.3,33131,2)
+88 ;;=^5001787
+89 ;;^UTILITY(U,$J,358.3,33132,0)
+90 ;;=C91.Z2^^102^1380^30
+91 ;;^UTILITY(U,$J,358.3,33132,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,33132,1,3,0)
+94 ;;=3^Lymphoid leukemia, in relapse NEC
+95 ;;^UTILITY(U,$J,358.3,33132,1,4,0)
+96 ;;=4^C91.Z2
+97 ;;^UTILITY(U,$J,358.3,33132,2)
+98 ;;=^5001788
+99 ;;^UTILITY(U,$J,358.3,33133,0)
+100 ;;=C92.01^^102^1380^6
+101 ;;^UTILITY(U,$J,358.3,33133,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,33133,1,3,0)
+104 ;;=3^Acute myeloblastic leukemia, in remission
+105 ;;^UTILITY(U,$J,358.3,33133,1,4,0)
+106 ;;=4^C92.01
+107 ;;^UTILITY(U,$J,358.3,33133,2)
+108 ;;=^5001790
+109 ;;^UTILITY(U,$J,358.3,33134,0)
+110 ;;=C92.41^^102^1380^10
+111 ;;^UTILITY(U,$J,358.3,33134,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,33134,1,3,0)
+114 ;;=3^Acute promyelocytic leukemia, in remission
+115 ;;^UTILITY(U,$J,358.3,33134,1,4,0)
+116 ;;=4^C92.41
+117 ;;^UTILITY(U,$J,358.3,33134,2)
+118 ;;=^5001802
+119 ;;^UTILITY(U,$J,358.3,33135,0)
+120 ;;=C92.51^^102^1380^8
+121 ;;^UTILITY(U,$J,358.3,33135,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,33135,1,3,0)
+124 ;;=3^Acute myelomonocytic leukemia, in remission
+125 ;;^UTILITY(U,$J,358.3,33135,1,4,0)
+126 ;;=4^C92.51
+127 ;;^UTILITY(U,$J,358.3,33135,2)
+128 ;;=^5001805
+129 ;;^UTILITY(U,$J,358.3,33136,0)
+130 ;;=C92.02^^102^1380^5
+131 ;;^UTILITY(U,$J,358.3,33136,1,0)
+132 ;;=^358.31IA^4^2
+133 ;;^UTILITY(U,$J,358.3,33136,1,3,0)
+134 ;;=3^Acute myeloblastic leukemia, in relapse
+135 ;;^UTILITY(U,$J,358.3,33136,1,4,0)
+136 ;;=4^C92.02
+137 ;;^UTILITY(U,$J,358.3,33136,2)
+138 ;;=^5001791
+139 ;;^UTILITY(U,$J,358.3,33137,0)
+140 ;;=C92.42^^102^1380^9
+141 ;;^UTILITY(U,$J,358.3,33137,1,0)
+142 ;;=^358.31IA^4^2
+143 ;;^UTILITY(U,$J,358.3,33137,1,3,0)
+144 ;;=3^Acute promyelocytic leukemia, in relapse
+145 ;;^UTILITY(U,$J,358.3,33137,1,4,0)
+146 ;;=4^C92.42
+147 ;;^UTILITY(U,$J,358.3,33137,2)
+148 ;;=^5001803
+149 ;;^UTILITY(U,$J,358.3,33138,0)
+150 ;;=C92.52^^102^1380^7
+151 ;;^UTILITY(U,$J,358.3,33138,1,0)
+152 ;;=^358.31IA^4^2
+153 ;;^UTILITY(U,$J,358.3,33138,1,3,0)
+154 ;;=3^Acute myelomonocytic leukemia, in relapse
+155 ;;^UTILITY(U,$J,358.3,33138,1,4,0)
+156 ;;=4^C92.52
+157 ;;^UTILITY(U,$J,358.3,33138,2)
+158 ;;=^5001806
+159 ;;^UTILITY(U,$J,358.3,33139,0)
+160 ;;=C92.11^^102^1380^18
+161 ;;^UTILITY(U,$J,358.3,33139,1,0)
+162 ;;=^358.31IA^4^2
+163 ;;^UTILITY(U,$J,358.3,33139,1,3,0)
+164 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
+165 ;;^UTILITY(U,$J,358.3,33139,1,4,0)
+166 ;;=4^C92.11
+167 ;;^UTILITY(U,$J,358.3,33139,2)
+168 ;;=^5001793
+169 ;;^UTILITY(U,$J,358.3,33140,0)
+170 ;;=C92.12^^102^1380^19
+171 ;;^UTILITY(U,$J,358.3,33140,1,0)
+172 ;;=^358.31IA^4^2
+173 ;;^UTILITY(U,$J,358.3,33140,1,3,0)
+174 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
+175 ;;^UTILITY(U,$J,358.3,33140,1,4,0)
+176 ;;=4^C92.12
+177 ;;^UTILITY(U,$J,358.3,33140,2)
+178 ;;=^5001794
+179 ;;^UTILITY(U,$J,358.3,33141,0)
+180 ;;=C92.21^^102^1380^13
+181 ;;^UTILITY(U,$J,358.3,33141,1,0)
+182 ;;=^358.31IA^4^2
+183 ;;^UTILITY(U,$J,358.3,33141,1,3,0)
+184 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
+185 ;;^UTILITY(U,$J,358.3,33141,1,4,0)
+186 ;;=4^C92.21
+187 ;;^UTILITY(U,$J,358.3,33141,2)
+188 ;;=^5001796
+189 ;;^UTILITY(U,$J,358.3,33142,0)
+190 ;;=C92.22^^102^1380^14
+191 ;;^UTILITY(U,$J,358.3,33142,1,0)
+192 ;;=^358.31IA^4^2
+193 ;;^UTILITY(U,$J,358.3,33142,1,3,0)
+194 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
+195 ;;^UTILITY(U,$J,358.3,33142,1,4,0)
+196 ;;=4^C92.22
+197 ;;^UTILITY(U,$J,358.3,33142,2)
+198 ;;=^5001797
+199 ;;^UTILITY(U,$J,358.3,33143,0)
+200 ;;=C93.01^^102^1380^3
+201 ;;^UTILITY(U,$J,358.3,33143,1,0)
+202 ;;=^358.31IA^4^2
+203 ;;^UTILITY(U,$J,358.3,33143,1,3,0)
+204 ;;=3^Acute monoblastic/monocytic leukemia, in remission
+205 ;;^UTILITY(U,$J,358.3,33143,1,4,0)
+206 ;;=4^C93.01
+207 ;;^UTILITY(U,$J,358.3,33143,2)
+208 ;;=^5001820
+209 ;;^UTILITY(U,$J,358.3,33144,0)
+210 ;;=C93.02^^102^1380^4
+211 ;;^UTILITY(U,$J,358.3,33144,1,0)
+212 ;;=^358.31IA^4^2
+213 ;;^UTILITY(U,$J,358.3,33144,1,3,0)
+214 ;;=3^Acute monoblastic/monocytic leukemia, in relapse
+215 ;;^UTILITY(U,$J,358.3,33144,1,4,0)
+216 ;;=4^C93.02
+217 ;;^UTILITY(U,$J,358.3,33144,2)
+218 ;;=^5001821
+219 ;;^UTILITY(U,$J,358.3,33145,0)
+220 ;;=C93.11^^102^1380^21
+221 ;;^UTILITY(U,$J,358.3,33145,1,0)
+222 ;;=^358.31IA^4^2
+223 ;;^UTILITY(U,$J,358.3,33145,1,3,0)
+224 ;;=3^Chronic myelomonocytic leukemia, in remission
+225 ;;^UTILITY(U,$J,358.3,33145,1,4,0)
+226 ;;=4^C93.11
+227 ;;^UTILITY(U,$J,358.3,33145,2)
+228 ;;=^5001823
+229 ;;^UTILITY(U,$J,358.3,33146,0)
+230 ;;=C93.12^^102^1380^20
+231 ;;^UTILITY(U,$J,358.3,33146,1,0)
+232 ;;=^358.31IA^4^2
+233 ;;^UTILITY(U,$J,358.3,33146,1,3,0)
+234 ;;=3^Chronic myelomonocytic leukemia, in relapse
+235 ;;^UTILITY(U,$J,358.3,33146,1,4,0)
+236 ;;=4^C93.12
+237 ;;^UTILITY(U,$J,358.3,33146,2)
+238 ;;=^5001824
+239 ;;^UTILITY(U,$J,358.3,33147,0)
+240 ;;=C93.91^^102^1380^40
+241 ;;^UTILITY(U,$J,358.3,33147,1,0)
+242 ;;=^358.31IA^4^2
+243 ;;^UTILITY(U,$J,358.3,33147,1,3,0)
+244 ;;=3^Monocytic leukemia, unspecified in remission
+245 ;;^UTILITY(U,$J,358.3,33147,1,4,0)
+246 ;;=4^C93.91
+247 ;;^UTILITY(U,$J,358.3,33147,2)
+248 ;;=^5001829
+249 ;;^UTILITY(U,$J,358.3,33148,0)
+250 ;;=C93.92^^102^1380^39
+251 ;;^UTILITY(U,$J,358.3,33148,1,0)
+252 ;;=^358.31IA^4^2
+253 ;;^UTILITY(U,$J,358.3,33148,1,3,0)
+254 ;;=3^Monocytic leukemia, unspecified in relapse
+255 ;;^UTILITY(U,$J,358.3,33148,1,4,0)
+256 ;;=4^C93.92
+257 ;;^UTILITY(U,$J,358.3,33148,2)
+258 ;;=^5001830
+259 ;;^UTILITY(U,$J,358.3,33149,0)
+260 ;;=E88.3^^102^1380^56
+261 ;;^UTILITY(U,$J,358.3,33149,1,0)
+262 ;;=^358.31IA^4^2
+263 ;;^UTILITY(U,$J,358.3,33149,1,3,0)
+264 ;;=3^Tumor lysis syndrome
+265 ;;^UTILITY(U,$J,358.3,33149,1,4,0)
+266 ;;=4^E88.3
+267 ;;^UTILITY(U,$J,358.3,33149,2)
+268 ;;=^338229
+269 ;;^UTILITY(U,$J,358.3,33150,0)
+270 ;;=C96.20^^102^1380^33
+271 ;;^UTILITY(U,$J,358.3,33150,1,0)
+272 ;;=^358.31IA^4^2
+273 ;;^UTILITY(U,$J,358.3,33150,1,3,0)
+274 ;;=3^Malignant mast cell neoplasm, unspecified
+275 ;;^UTILITY(U,$J,358.3,33150,1,4,0)
+276 ;;=4^C96.20
+277 ;;^UTILITY(U,$J,358.3,33150,2)
+278 ;;=^5151293
+279 ;;^UTILITY(U,$J,358.3,33151,0)
+280 ;;=C96.21^^102^1380^35
+281 ;;^UTILITY(U,$J,358.3,33151,1,0)
+282 ;;=^358.31IA^4^2
+283 ;;^UTILITY(U,$J,358.3,33151,1,3,0)
+284 ;;=3^Mastocytosis, aggressive systemic
+285 ;;^UTILITY(U,$J,358.3,33151,1,4,0)
+286 ;;=4^C96.21
+287 ;;^UTILITY(U,$J,358.3,33151,2)
+288 ;;=^5151294
+289 ;;^UTILITY(U,$J,358.3,33152,0)
+290 ;;=C96.22^^102^1380^52
+291 ;;^UTILITY(U,$J,358.3,33152,1,0)
+292 ;;=^358.31IA^4^2
+293 ;;^UTILITY(U,$J,358.3,33152,1,3,0)
+294 ;;=3^Sarcoma, mast cell
+295 ;;^UTILITY(U,$J,358.3,33152,1,4,0)
+296 ;;=4^C96.22
+297 ;;^UTILITY(U,$J,358.3,33152,2)
+298 ;;=^5151295
+299 ;;^UTILITY(U,$J,358.3,33153,0)
+300 ;;=C96.29^^102^1380^45
+301 ;;^UTILITY(U,$J,358.3,33153,1,0)
+302 ;;=^358.31IA^4^2
+303 ;;^UTILITY(U,$J,358.3,33153,1,3,0)
+304 ;;=3^Neoplasm, mast cell, oth malignant
+305 ;;^UTILITY(U,$J,358.3,33153,1,4,0)
+306 ;;=4^C96.29
+307 ;;^UTILITY(U,$J,358.3,33153,2)
+308 ;;=^5151296
+309 ;;^UTILITY(U,$J,358.3,33154,0)
+310 ;;=D47.01^^102^1380^36
+311 ;;^UTILITY(U,$J,358.3,33154,1,0)
+312 ;;=^358.31IA^4^2
+313 ;;^UTILITY(U,$J,358.3,33154,1,3,0)
+314 ;;=3^Mastocytosis, cutaneous
+315 ;;^UTILITY(U,$J,358.3,33154,1,4,0)
+316 ;;=4^D47.01
+317 ;;^UTILITY(U,$J,358.3,33154,2)
+318 ;;=^5151297
+319 ;;^UTILITY(U,$J,358.3,33155,0)
+320 ;;=D47.02^^102^1380^37
+321 ;;^UTILITY(U,$J,358.3,33155,1,0)
+322 ;;=^358.31IA^4^2
+323 ;;^UTILITY(U,$J,358.3,33155,1,3,0)
+324 ;;=3^Mastocytosis, systemic
+325 ;;^UTILITY(U,$J,358.3,33155,1,4,0)
+326 ;;=4^D47.02
+327 ;;^UTILITY(U,$J,358.3,33155,2)
+328 ;;=^5151298
+329 ;;^UTILITY(U,$J,358.3,33156,0)
+330 ;;=D47.09^^102^1380^46
+331 ;;^UTILITY(U,$J,358.3,33156,1,0)
+332 ;;=^358.31IA^4^2
+333 ;;^UTILITY(U,$J,358.3,33156,1,3,0)
+334 ;;=3^Neoplasms, mast cell, oth, of uncertain behavior
+335 ;;^UTILITY(U,$J,358.3,33156,1,4,0)
+336 ;;=4^D47.09
+337 ;;^UTILITY(U,$J,358.3,33156,2)
+338 ;;=^5151299
+339 ;;^UTILITY(U,$J,358.3,33157,0)
+340 ;;=C62.11^^102^1381^2
+341 ;;^UTILITY(U,$J,358.3,33157,1,0)
+342 ;;=^358.31IA^4^2
+343 ;;^UTILITY(U,$J,358.3,33157,1,3,0)
+344 ;;=3^Malignant neoplasm of descended right testis
+345 ;;^UTILITY(U,$J,358.3,33157,1,4,0)
+346 ;;=4^C62.11
+347 ;;^UTILITY(U,$J,358.3,33157,2)
+348 ;;=^5001234
+349 ;;^UTILITY(U,$J,358.3,33158,0)
+350 ;;=C62.12^^102^1381^1
+351 ;;^UTILITY(U,$J,358.3,33158,1,0)
+352 ;;=^358.31IA^4^2
+353 ;;^UTILITY(U,$J,358.3,33158,1,3,0)
+354 ;;=3^Malignant neoplasm of descended left testis
+355 ;;^UTILITY(U,$J,358.3,33158,1,4,0)
+356 ;;=4^C62.12
+357 ;;^UTILITY(U,$J,358.3,33158,2)
+358 ;;=^5001235
+359 ;;^UTILITY(U,$J,358.3,33159,0)
+360 ;;=M81.0^^102^1382^1
+361 ;;^UTILITY(U,$J,358.3,33159,1,0)
+362 ;;=^358.31IA^4^2
+363 ;;^UTILITY(U,$J,358.3,33159,1,3,0)
+364 ;;=3^Age-related osteoporosis w/o current pathological fracture
+365 ;;^UTILITY(U,$J,358.3,33159,1,4,0)
+366 ;;=4^M81.0
+367 ;;^UTILITY(U,$J,358.3,33159,2)
+368 ;;=^5013555
+369 ;;^UTILITY(U,$J,358.3,33160,0)
+370 ;;=E10.9^^102^1382^5
+371 ;;^UTILITY(U,$J,358.3,33160,1,0)
+372 ;;=^358.31IA^4^2
+373 ;;^UTILITY(U,$J,358.3,33160,1,3,0)
+374 ;;=3^Diabetes Type 1 w/o Complications
+375 ;;^UTILITY(U,$J,358.3,33160,1,4,0)
+376 ;;=4^E10.9
+377 ;;^UTILITY(U,$J,358.3,33160,2)
+378 ;;=^5002626
+379 ;;^UTILITY(U,$J,358.3,33161,0)
+380 ;;=E11.9^^102^1382^8
+381 ;;^UTILITY(U,$J,358.3,33161,1,0)
+382 ;;=^358.31IA^4^2
+383 ;;^UTILITY(U,$J,358.3,33161,1,3,0)
+384 ;;=3^Diabetes Type 2 w/o Complications
+385 ;;^UTILITY(U,$J,358.3,33161,1,4,0)
+386 ;;=4^E11.9
+387 ;;^UTILITY(U,$J,358.3,33161,2)
+388 ;;=^5002666
+389 ;;^UTILITY(U,$J,358.3,33162,0)
+390 ;;=E11.10^^102^1382^7
+391 ;;^UTILITY(U,$J,358.3,33162,1,0)
+392 ;;=^358.31IA^4^2
+393 ;;^UTILITY(U,$J,358.3,33162,1,3,0)
+394 ;;=3^Diabetes Type 2 w/ Ketoacidosis w/o Coma
+395 ;;^UTILITY(U,$J,358.3,33162,1,4,0)
+396 ;;=4^E11.10
+397 ;;^UTILITY(U,$J,358.3,33162,2)
+398 ;;=^5151300
+399 ;;^UTILITY(U,$J,358.3,33163,0)
+400 ;;=E11.11^^102^1382^6
+401 ;;^UTILITY(U,$J,358.3,33163,1,0)
+402 ;;=^358.31IA^4^2
+403 ;;^UTILITY(U,$J,358.3,33163,1,3,0)
+404 ;;=3^Diabetes Type 2 w/ Ketoacidosis w/ Coma
+405 ;;^UTILITY(U,$J,358.3,33163,1,4,0)
+406 ;;=4^E11.11
+407 ;;^UTILITY(U,$J,358.3,33163,2)
+408 ;;=^5151301
+409 ;;^UTILITY(U,$J,358.3,33164,0)
+410 ;;=E85.81^^102^1382^2
+411 ;;^UTILITY(U,$J,358.3,33164,1,0)
+412 ;;=^358.31IA^4^2
+413 ;;^UTILITY(U,$J,358.3,33164,1,3,0)
+414 ;;=3^Amyloidosis,Light Chain (AL)
+415 ;;^UTILITY(U,$J,358.3,33164,1,4,0)
+416 ;;=4^E85.81
+417 ;;^UTILITY(U,$J,358.3,33164,2)
+418 ;;=^5151302
+419 ;;^UTILITY(U,$J,358.3,33165,0)
+420 ;;=E85.82^^102^1382^4
+421 ;;^UTILITY(U,$J,358.3,33165,1,0)
+422 ;;=^358.31IA^4^2
+423 ;;^UTILITY(U,$J,358.3,33165,1,3,0)
+424 ;;=3^Amyloidosis,Wild-Type Transthyretin-Related (ATTR)
+425 ;;^UTILITY(U,$J,358.3,33165,1,4,0)
+426 ;;=4^E85.82
+427 ;;^UTILITY(U,$J,358.3,33165,2)
+428 ;;=^5151303
+429 ;;^UTILITY(U,$J,358.3,33166,0)
+430 ;;=E85.89^^102^1382^3
+431 ;;^UTILITY(U,$J,358.3,33166,1,0)
+432 ;;=^358.31IA^4^2
+433 ;;^UTILITY(U,$J,358.3,33166,1,3,0)
+434 ;;=3^Amyloidosis,Other
+435 ;;^UTILITY(U,$J,358.3,33166,1,4,0)
+436 ;;=4^E85.89
+437 ;;^UTILITY(U,$J,358.3,33166,2)
+438 ;;=^334034
+439 ;;^UTILITY(U,$J,358.3,33167,0)
+440 ;;=R10.9^^102^1383^2
+441 ;;^UTILITY(U,$J,358.3,33167,1,0)
+442 ;;=^358.31IA^4^2
+443 ;;^UTILITY(U,$J,358.3,33167,1,3,0)
+444 ;;=3^Abdominal Pain,Unspec
+445 ;;^UTILITY(U,$J,358.3,33167,1,4,0)
+446 ;;=4^R10.9
+447 ;;^UTILITY(U,$J,358.3,33167,2)
+448 ;;=^5019230
+449 ;;^UTILITY(U,$J,358.3,33168,0)
+450 ;;=R10.11^^102^1383^47
+451 ;;^UTILITY(U,$J,358.3,33168,1,0)
+452 ;;=^358.31IA^4^2
+453 ;;^UTILITY(U,$J,358.3,33168,1,3,0)
+454 ;;=3^Right upper quadrant pain
+455 ;;^UTILITY(U,$J,358.3,33168,1,4,0)
+456 ;;=4^R10.11
+457 ;;^UTILITY(U,$J,358.3,33168,2)
+458 ;;=^5019206
+459 ;;^UTILITY(U,$J,358.3,33169,0)
+460 ;;=R10.31^^102^1383^46
+461 ;;^UTILITY(U,$J,358.3,33169,1,0)
+462 ;;=^358.31IA^4^2
+463 ;;^UTILITY(U,$J,358.3,33169,1,3,0)
+464 ;;=3^Right lower quadrant pain
+465 ;;^UTILITY(U,$J,358.3,33169,1,4,0)
+466 ;;=4^R10.31
+467 ;;^UTILITY(U,$J,358.3,33169,2)
+468 ;;=^5019211
+469 ;;^UTILITY(U,$J,358.3,33170,0)
+470 ;;=R10.84^^102^1383^1
+471 ;;^UTILITY(U,$J,358.3,33170,1,0)
+472 ;;=^358.31IA^4^2
+473 ;;^UTILITY(U,$J,358.3,33170,1,3,0)
+474 ;;=3^Abdominal Pain,Generalized
+475 ;;^UTILITY(U,$J,358.3,33170,1,4,0)
+476 ;;=4^R10.84
+477 ;;^UTILITY(U,$J,358.3,33170,2)
+478 ;;=^5019229
+479 ;;^UTILITY(U,$J,358.3,33171,0)
+480 ;;=R10.10^^102^1383^49
+481 ;;^UTILITY(U,$J,358.3,33171,1,0)
+482 ;;=^358.31IA^4^2
+483 ;;^UTILITY(U,$J,358.3,33171,1,3,0)
+484 ;;=3^Upper abdominal pain, unspecified
+485 ;;^UTILITY(U,$J,358.3,33171,1,4,0)
+486 ;;=4^R10.10
+487 ;;^UTILITY(U,$J,358.3,33171,2)
+488 ;;=^5019205
+489 ;;^UTILITY(U,$J,358.3,33172,0)
+490 ;;=R10.30^^102^1383^32
+491 ;;^UTILITY(U,$J,358.3,33172,1,0)
+492 ;;=^358.31IA^4^2
+493 ;;^UTILITY(U,$J,358.3,33172,1,3,0)
+494 ;;=3^Lower abdominal pain, unspecified
+495 ;;^UTILITY(U,$J,358.3,33172,1,4,0)
+496 ;;=4^R10.30
+497 ;;^UTILITY(U,$J,358.3,33172,2)
+498 ;;=^5019210
+499 ;;^UTILITY(U,$J,358.3,33173,0)
+500 ;;=R10.2^^102^1383^40
+501 ;;^UTILITY(U,$J,358.3,33173,1,0)
+502 ;;=^358.31IA^4^2
+503 ;;^UTILITY(U,$J,358.3,33173,1,3,0)
+504 ;;=3^Pelvic and perineal pain
+505 ;;^UTILITY(U,$J,358.3,33173,1,4,0)
+506 ;;=4^R10.2
+507 ;;^UTILITY(U,$J,358.3,33173,2)
+508 ;;=^5019209
+509 ;;^UTILITY(U,$J,358.3,33174,0)
+510 ;;=R18.8^^102^1383^9
+511 ;;^UTILITY(U,$J,358.3,33174,1,0)
+512 ;;=^358.31IA^4^2
+513 ;;^UTILITY(U,$J,358.3,33174,1,3,0)
+514 ;;=3^Ascites NEC
+515 ;;^UTILITY(U,$J,358.3,33174,1,4,0)
+516 ;;=4^R18.8
+517 ;;^UTILITY(U,$J,358.3,33174,2)
+518 ;;=^5019253
+519 ;;^UTILITY(U,$J,358.3,33175,0)
+520 ;;=R19.7^^102^1383^17
+521 ;;^UTILITY(U,$J,358.3,33175,1,0)
+522 ;;=^358.31IA^4^2
+523 ;;^UTILITY(U,$J,358.3,33175,1,3,0)
+524 ;;=3^Diarrhea, unspecified
+525 ;;^UTILITY(U,$J,358.3,33175,1,4,0)
+526 ;;=4^R19.7
+527 ;;^UTILITY(U,$J,358.3,33175,2)
+528 ;;=^5019276
+529 ;;^UTILITY(U,$J,358.3,33176,0)
+530 ;;=R11.2^^102^1383^36
+531 ;;^UTILITY(U,$J,358.3,33176,1,0)
+532 ;;=^358.31IA^4^2
+533 ;;^UTILITY(U,$J,358.3,33176,1,3,0)
+534 ;;=3^Nausea with vomiting, unspecified
+535 ;;^UTILITY(U,$J,358.3,33176,1,4,0)
+536 ;;=4^R11.2
+537 ;;^UTILITY(U,$J,358.3,33176,2)
+538 ;;=^5019237
+539 ;;^UTILITY(U,$J,358.3,33177,0)
+540 ;;=R11.0^^102^1383^35
+541 ;;^UTILITY(U,$J,358.3,33177,1,0)
+542 ;;=^358.31IA^4^2
+543 ;;^UTILITY(U,$J,358.3,33177,1,3,0)
+544 ;;=3^Nausea
+545 ;;^UTILITY(U,$J,358.3,33177,1,4,0)
+546 ;;=4^R11.0
+547 ;;^UTILITY(U,$J,358.3,33177,2)
+548 ;;=^5019231
+549 ;;^UTILITY(U,$J,358.3,33178,0)
+550 ;;=R11.10^^102^1383^51
+551 ;;^UTILITY(U,$J,358.3,33178,1,0)
+552 ;;=^358.31IA^4^2
+553 ;;^UTILITY(U,$J,358.3,33178,1,3,0)
+554 ;;=3^Vomiting, unspecified
+555 ;;^UTILITY(U,$J,358.3,33178,1,4,0)
+556 ;;=4^R11.10
+557 ;;^UTILITY(U,$J,358.3,33178,2)
+558 ;;=^5019232
+559 ;;^UTILITY(U,$J,358.3,33179,0)
+560 ;;=R11.11^^102^1383^50
+561 ;;^UTILITY(U,$J,358.3,33179,1,0)
+562 ;;=^358.31IA^4^2
+563 ;;^UTILITY(U,$J,358.3,33179,1,3,0)
+564 ;;=3^Vomiting without nausea
+565 ;;^UTILITY(U,$J,358.3,33179,1,4,0)
+566 ;;=4^R11.11
+567 ;;^UTILITY(U,$J,358.3,33179,2)
+568 ;;=^5019233
+569 ;;^UTILITY(U,$J,358.3,33180,0)
+570 ;;=R11.12^^102^1383^42
+571 ;;^UTILITY(U,$J,358.3,33180,1,0)
+572 ;;=^358.31IA^4^2
+573 ;;^UTILITY(U,$J,358.3,33180,1,3,0)
+574 ;;=3^Projectile vomiting
+575 ;;^UTILITY(U,$J,358.3,33180,1,4,0)
+576 ;;=4^R11.12
+577 ;;^UTILITY(U,$J,358.3,33180,2)
+578 ;;=^5019234
+579 ;;^UTILITY(U,$J,358.3,33181,0)
+580 ;;=R62.7^^102^1383^5
+581 ;;^UTILITY(U,$J,358.3,33181,1,0)
+582 ;;=^358.31IA^4^2
+583 ;;^UTILITY(U,$J,358.3,33181,1,3,0)
+584 ;;=3^Adult failure to thrive
+585 ;;^UTILITY(U,$J,358.3,33181,1,4,0)
+586 ;;=4^R62.7
+587 ;;^UTILITY(U,$J,358.3,33181,2)
+588 ;;=^322019
+589 ;;^UTILITY(U,$J,358.3,33182,0)
+590 ;;=R60.9^^102^1383^19
+591 ;;^UTILITY(U,$J,358.3,33182,1,0)
+592 ;;=^358.31IA^4^2
+593 ;;^UTILITY(U,$J,358.3,33182,1,3,0)
+594 ;;=3^Edema, unspecified
+595 ;;^UTILITY(U,$J,358.3,33182,1,4,0)
+596 ;;=4^R60.9
+597 ;;^UTILITY(U,$J,358.3,33182,2)
+598 ;;=^5019534
+599 ;;^UTILITY(U,$J,358.3,33183,0)
+600 ;;=R60.1^^102^1383^20
+601 ;;^UTILITY(U,$J,358.3,33183,1,0)
+602 ;;=^358.31IA^4^2
+603 ;;^UTILITY(U,$J,358.3,33183,1,3,0)
+604 ;;=3^Edema,Generalized
+605 ;;^UTILITY(U,$J,358.3,33183,1,4,0)
+606 ;;=4^R60.1
+607 ;;^UTILITY(U,$J,358.3,33183,2)
+608 ;;=^5019533
+609 ;;^UTILITY(U,$J,358.3,33184,0)
+610 ;;=R60.0^^102^1383^21
+611 ;;^UTILITY(U,$J,358.3,33184,1,0)
+612 ;;=^358.31IA^4^2
+613 ;;^UTILITY(U,$J,358.3,33184,1,3,0)
+614 ;;=3^Edema,Localized
+615 ;;^UTILITY(U,$J,358.3,33184,1,4,0)
+616 ;;=4^R60.0
+617 ;;^UTILITY(U,$J,358.3,33184,2)
+618 ;;=^5019532
+619 ;;^UTILITY(U,$J,358.3,33185,0)
+620 ;;=L29.9^^102^1383^45
+621 ;;^UTILITY(U,$J,358.3,33185,1,0)
+622 ;;=^358.31IA^4^2
+623 ;;^UTILITY(U,$J,358.3,33185,1,3,0)
+624 ;;=3^Pruritus, unspecified
+625 ;;^UTILITY(U,$J,358.3,33185,1,4,0)
+626 ;;=4^L29.9
+627 ;;^UTILITY(U,$J,358.3,33185,2)
+628 ;;=^5009153
+629 ;;^UTILITY(U,$J,358.3,33186,0)
+630 ;;=I95.9^^102^1383^28
+631 ;;^UTILITY(U,$J,358.3,33186,1,0)
+632 ;;=^358.31IA^4^2
+633 ;;^UTILITY(U,$J,358.3,33186,1,3,0)
+634 ;;=3^Hypotension, unspecified
+635 ;;^UTILITY(U,$J,358.3,33186,1,4,0)
+636 ;;=4^I95.9
+637 ;;^UTILITY(U,$J,358.3,33186,2)
+638 ;;=^5008080
+639 ;;^UTILITY(U,$J,358.3,33187,0)
+640 ;;=I10.^^102^1383^24
+641 ;;^UTILITY(U,$J,358.3,33187,1,0)
+642 ;;=^358.31IA^4^2
+643 ;;^UTILITY(U,$J,358.3,33187,1,3,0)
+644 ;;=3^Essential (primary) hypertension
+645 ;;^UTILITY(U,$J,358.3,33187,1,4,0)
+646 ;;=4^I10.
+647 ;;^UTILITY(U,$J,358.3,33187,2)
+648 ;;=^5007062
+649 ;;^UTILITY(U,$J,358.3,33188,0)
+650 ;;=G89.29^^102^1383^13
+651 ;;^UTILITY(U,$J,358.3,33188,1,0)
+652 ;;=^358.31IA^4^2
+653 ;;^UTILITY(U,$J,358.3,33188,1,3,0)
+654 ;;=3^Chronic Pain NEC
+655 ;;^UTILITY(U,$J,358.3,33188,1,4,0)
+656 ;;=4^G89.29
+657 ;;^UTILITY(U,$J,358.3,33188,2)
+658 ;;=^5004158
+659 ;;^UTILITY(U,$J,358.3,33189,0)
+660 ;;=F41.9^^102^1383^8
+661 ;;^UTILITY(U,$J,358.3,33189,1,0)
+662 ;;=^358.31IA^4^2
+663 ;;^UTILITY(U,$J,358.3,33189,1,3,0)
+664 ;;=3^Anxiety disorder, unspecified
+665 ;;^UTILITY(U,$J,358.3,33189,1,4,0)
+666 ;;=4^F41.9
+667 ;;^UTILITY(U,$J,358.3,33189,2)
+668 ;;=^5003567
+669 ;;^UTILITY(U,$J,358.3,33190,0)
+670 ;;=F33.9^^102^1383^34
+671 ;;^UTILITY(U,$J,358.3,33190,1,0)
+672 ;;=^358.31IA^4^2
+673 ;;^UTILITY(U,$J,358.3,33190,1,3,0)
+674 ;;=3^Major depressive disorder, recurrent, unspecified
+675 ;;^UTILITY(U,$J,358.3,33190,1,4,0)
+676 ;;=4^F33.9
